Latest news with #Genomics
Business Upturn
3 days ago
- Business
- Business Upturn
Protein Industries Canada Launches $15 Million in Genomics and AI Programs to Strengthen Canada's Agrifood Sector
Regina, SK, May 29, 2025 (GLOBE NEWSWIRE) — Today, Protein Industries Canada announced an additional $15 million in funding provided by the Government of Canada. Focused on two key streams—Genomics and Artificial Intelligence—this new investment will help strengthen Canada's agriculture sector and domestic food supply chain by bringing new tools to plant-breeders, farmers, ingredient processors and food manufacturers. By advancing genomics and AI technologies, these programs will enable farmers and companies across Canada's agrifood sector to build a more resilient, efficient and sustainable food system. This full value-chain approach will expand the range of Canadian-made ingredient options while also creating new economic opportunities—bringing the country closer to realizing its $25 billion agrifood growth potential. 'Investing in genomics and artificial intelligence is investing in our future, helping build a more prosperous and competitive Canada,' said the Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions. 'Administered by the Protein Industries Cluster, this new funding will support innovative solutions that will contribute to a more resilient, productive and sustainable agri-food sector.' Through the new five-year Genomics Stream, Protein Industries Canada will invest $7 million into the commercialization of new and improved broad-acre crop varieties, with a focus on pulse and cereal crops. Projects under the stream will apply genomic tools in plant breeding and variety development to meet industry demand, aligning innovation across the value-chain, from growers to ingredient manufacturers. The additional $8 million into artificial intelligence programming will boost Protein Industries Canada's current investment under the Government of Canada's Pan-Canadian Artificial Intelligence Strategy. Projects that will be considered may involve: the development of tools that accelerate seed genetic work; supply chain optimization; on-farm information gathering; quality assurance and food safety protocols; and ingredient and food formulation. 'This new investment will deliver value across the entire supply chain, starting with enhanced genetics that improve crop functionality and provide farmers with more resilient, high-performing options,' CEO of Protein Industries Canada Robert Hunter said. 'At the same time, our investment into artificial intelligence will support the development of tools that boost on-farm productivity and sustainability. Together, these advancements—combined with our full value-chain approach—will strengthen Canada's position as a global supplier of nutritious, functional plant-based food, feed and ingredients, while contributing to our goal of building a $25 billion industry for Canada.' Companies interested in applying to either program stream are asked to visit Protein Industries Canada's website. Consortiums who may be eligible for the Genomics program can find more information at while companies interested in the AI program should visit Both the Genomics and Artificial Intelligence Streams are open on a continual intake basis. Interested companies are asked to fill out the forms at the bottom of each the Technology and Artificial Intelligence pages. If a project meets initial eligibility requirements, Protein Industries Canada's Project team will reach out to schedule a preliminary meeting. This first meeting must be held prior to an EOI being submitted. EOIs will be reviewed on an ongoing basis, allowing successful submissions to move to the next step in the process in a timely manner. Protein Industries Canada is one of Canada's five Global Innovation Clusters. Protein Industries Canada and its members are working to embrace the $25 billion opportunity presented by Canada's plant-based ingredient manufacturing, food processing and feed sectors. Through investments into innovative projects, Protein Industries Canada is adding value to, and creating new markets for, Canadian crops, generating local jobs and supporting new economic development in locations across Canada. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
13-05-2025
- Business
- Yahoo
RevoluGen and ProteoQuest Join Forces to Bring Fire Monkey HMW-DNA Extraction to China and Asia Pacific's Fast Growing DNA Sequencing-based Genomics Markets
HADFIELD, United Kingdom and HONG KONG, May 13, 2025 (GLOBE NEWSWIRE) -- UK genomics tools company, RevoluGen Limited and Hong Kong-based life sciences distributor ProteoQuest Technology Co. Ltd are pleased to announce they have entered into an agreement for the distribution of Fire Monkey™ High Molecular Weight (HMW) DNA extraction kits across China, including Hong Kong and Taiwan. Fire Monkey is DNA sequencing platform agnostic suitable for both long- and short-read sequencing and enables cost-efficient hybrid sequencing (Oxford Nanopore Technologies (ONT)-Illumina or other short-read options), allowing flexibility for users. Fire Monkey is the world's first spin column based Nucleic Acid Isolation and Purification (NAIP) kit that extracts HMW-DNA in a rapid, simple and user-friendly protocol. Extracts do not require overnight resting and are therefore ready for use in ONT library workflows. DNA extraction is the first essential step in DNA sequencing, critical to genomics applications. RevoluGen's patent-protected technology is derived from an innovative chemistry which allows extraction of HMW-DNA using a high g-force (up to 14,000 x G) but which does not break down the long and fragile DNA molecules as much as any standard spin-column technologies. Fire Monkey performs HMW-DNA extraction from bacterial and animal cells resulting in extracts with a length of approximately 100kb. Under the terms of the agreement, RevoluGen has granted ProteoQuest the rights to promote, market and sell Fire Monkey products to its molecular biology users in Greater China. Founded by Shang Tsai, previously of Tecan, with whom RevoluGen has a collaboration, ProteoQuest is a leading life science distributor of complete workflow products in molecular biology that will accelerate the commercialisation of Fire Monkey in the vibrant Asia Pacific markets for DNA sequencing and genomics. 'With Fire Monkey HMW-DNA extraction already proven and in commercial use in leading laboratories in the UK, including the UK Government's Health Security Agency (UKHSA), ProteoQuest is ideally placed to bring Fire Monkey to the rapidly growing genomic-based markets in China,' said Dr Georgios Patsos, inventor of the Fire Monkey technology and CSO at RevoluGen. Shang Tsai, Founder and CEO at ProteoQuest said, 'With more labs looking to sequence DNA for both academic and the burgeoning genomics applications, there is an increasing need to extract high molecular weight DNA with the flexibility of hybrid sequencing protocols. RevoluGen's HMW-DNA extraction is already proven to outperform competitor technologies and we are convinced that Fire Monkey has the potential to be adopted as the standard protocol where HMW-DNA extraction is required.' The World Health Organisation, UKHSA, Genomics England (UK Department of Health and Social Care) and others have all highlighted the importance of performing both short (Ilumina) and long (ONT) reads for the same biological sample to successfully predict emerging threats within the food chain, provide accurate risk assessments during pathogen outbreak investigations and advance precision medicine for patients with cancer and other genetic disease. Dr Georgios Patsos, inventor of the Fire Monkey technology and CSO at RevoluGen added, 'Being a familiar and user-friendly spin column process, Fire Monkey is ideal for extraction of DNA for on all sequencing platforms giving users the benefit of one extraction for both their initial short-read sequencing and for any subsequent long-read sequencing that can therefore be performed on exactly the same original sample without any further cost, reprocessing problems or potential handling errors. By only needing to do one extraction rather than two it can reduce sample handling and storage significantly enabling cost effective hybrid assemblies.' Initially available to Chinese users in commercial kit format for manual extractions, RevoluGen has developed semi-automated extraction on microtitre plates as well as fully automated DNA extraction using magnetic beads, enabling seamless integration into robotic workflows, unlike other HMW-DNA extraction methods. The global genome sequencing market size is calculated at US$ 22.63 billion in 2024, with expected grow to US$ 26.31 billion in 2025, and is projected to reach around US$ 101.93 billion by 2034. The market is expanding at a CAGR of 16.24% between 2025 and 2034. By product, the consumables segment composes the major share of the genome sequencing market in 2024, including NAIP. The next-generation sequencing (NGS) segment is the largest revenue contributor to the market and China has one of the fastest growing and most advanced markets. Domestic biotech innovation has been a focus of recent Chinese government efforts. The expansion of the industry has been greatly aided by a new national plan. Through its "Healthy China 2030" plan, which emphasizes medical innovation and expanding access to medications, China pledged to improve health outcomes for the Chinese people. Media contacts: For RevoluGen Sue Charles, Director and Head of Corporate Communications Tel +44 (0)7968 72658586, sue@ For ProteoQuest Derek Liu, Managing Director Tel +86 18616545477 / +86 21 58555098, scope509@ About RevoluGen - RevoluGen is a privately held scientific research and development company commercialising molecular tools with a specific focus on rapidly extracting long and pure DNA fragments from cells. RevoluGen's Nucleic Acid Isolation and Purification (NAIP) products have broad application across all of both short- and long-read DNA sequencing technologies, including their use in particular for population genomics, epidemiological mutation screening and antibiotic microbial resistance gene monitoring. The Company headquarters, R&D, manufacturing and direct customer sales and support are based in the UK. RevoluGen serves customers worldwide and has secured agreements with world-leading molecular biology tools companies including Merck KGaA (sales), ProteoQuest, Welgene and BioEntist (distribution), Cytiva (manufacturing), Tecan (96-well plates and automation) and A4P (logistics). Follow us on Twitter and LinkedIn Watch our film and animation About ProteoQuest ProteoQuest is a privately held company headquartered in Hong Kong with focus on commercial distribution of genomic, proteomic, and celomic tools. The company offers technical support and service to all customers across China/Hong Kong/Taiwan. In addition to supporting and distributing consumable reagents from top solution providers, ProteoQuest also helps customer design and provide automated solutions.
Telegraph
27-04-2025
- Health
- Telegraph
Do you have the fat gene? This test could soon tell you
For some, it can seem like a never-ending battle to keep the pounds off. Where friends and family appear able to indulge with little consequences, there are those who feel like, no matter how healthily they eat, the scales just keep going up. Scientists now think people who struggle with their weight may have drawn the genetic short-straw – and soon people will be able to find out if their genes are to blame for the struggle. Work has begun in the UK on developing new tests that will spot if someone has 'fat genes'. The project, which seeks to create simple blood or saliva tests, is being undertaken by a team at Oxford gene start-up Genomics and Novo Nordisk, the Danish drug giant behind blockbuster weight-loss drug Wegovy and Ozempic. The tests are expected to work by identifying if someone has the differences in their DNA that make them more prone to obesity. Sir Peter Donnelly, chief executive of Genomics, said genetics is 'four times more important than lifestyle factors' when it comes to mapping if someone will become obese. Studies have suggested that somebody with unhelpful genetics is around 10 times more likely to be obese in middle age than someone with helpful genes. It can mean those people with these obesity genes have to work much harder to keep on top of their weight. Research in the US has found that someone with 'unhelpful genetics' would have to walk 10,000 more steps than someone with 'helpful genetics' to maintain a healthy weight. Sir Peter said: 'There's not a single gene which matters for obesity or for heart disease or other diseases. There are more than a million places in our DNA, each of which has a tiny impact on our propensity for obesity.' Scientists from Genomics will create an algorithm that can accurately map which DNA differences are most important in determining someone's likelihood of becoming obese. The team says they expect to launch tests within the next few years. Sir Peter said change was needed over how people view obesity, adding: 'We have to start thinking about obesity as a condition, rather than some consequence of poor willpower.' It comes as governments step up attempts to tackle the obesity crisis amid concerns that more people are becoming severely overweight. Figures released last month revealed that more than three in four adults in the UK will be obese or overweight by 2050. Nadeem Sarwar, who heads up Novo Nordisk's 'transformational prevention unit', said the UK could be a pioneer in tackling obesity by stopping it before the disease progresses. Novo Nordisk recently set up the 'transformational prevention unit' (TPU), which is anchored in the UK, to 'predict, pre-empt and prevent' obesity. Alongside the tests for obesity, Novo Nordisk is also seeking to develop treatments that can then be targetted to those who test positive for fat genes. Mr Sarwar said: 'Just telling someone, 'You're high risk for disease, good luck' is not really going to help them that much. So at the TPU, we're putting in as much effort on developing products that will help prevent the risk as much as we are to pre-empt the risk.' Wes Streeing, the Health Secretary, has said he wants to shift the NHS's focus from 'sickness to prevention'. Already, the Government has clamped down on junk food ads in an attempt to curb obesity levels, saying the disease costs the NHS billions of pounds every year. Mr Sarwar said: 'The UK, I think rightly, is emphasising the importance of prevention.' Novo Nordisk is developing more preventative treatments for obesity as competition heats up in the weight-loss market. Up until this point, Novo Nordisk has been outselling US rival Eli Lilly for its weight-loss treatments, which help people lose an average of 15pc of their body mass by suppressing appetite. However, the two companies have been battling to break new ground on weight-loss treatments. Earlier this month, Novo Nordisk's shares dropped as much as 7pc after Eli Lilly released trial data suggesting it had created a weight-loss pill that worked just as well as Wegovy.
Yahoo
09-03-2025
- Business
- Yahoo
Why Does Nancy Pelosi Like Tempus AI (TEM) Stock So Much?
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Rep. Nancy Pelosi (D-CA) stands to make a massive profit on an options trade she made on an AI stock. The Nancy Pelosi tracker on X cited Pelosi's SEC disclosures, which show she bought 50 call options of Tempus AI (NASDAQ TEM) stock options at a strike price of $20. Tempus AI's stock surged by 183% after Pelosi's disclosure became public. Keep reading to discover why Pelosi likes Tempus AI so much. The surge in Tempus stock is indicative of how many investors monitor and mimic Pelosi's trading activity. They do that for one simple reason: she has an uncanny knack for making profitable trades. Cryptopolitan quotes information from the Unusual Whales website showing Pelosi investments generated an impressive 70.9% return in 2024. The S&P 500's 24.9% return looks paltry by comparison. Don't Miss: Coinbase's latest promo gets you up to $200 in crypto (Seriously!) — CEO of Integris gathered a team of senior investment managers who have $34.22 billion in combined owned and managed assets in the West Coast — In fairness to Tempus AI, Pelosi can't take all the credit for their stock being hot. The AI sector is booming and Tempus has a proprietary AI analytics program, Lens. More importantly, Tempus AI just announced a partnership with the Institute for Follicular Lymphoma Innovation, which will use Lens to help develop cures for follicular lymphoma. Cryptopolitan reported that the global market for follicular lymphoma cures is expected to be worth $4.65 billion by 2030. Tempus AI also just released its Q4 2024 earnings and the highlights include: Annual revenue of $693.4 million—a 30% year-on-year increase $381.1 million increase in annual gross profit—33.2% year-on-year increase $104.7 million in adjusted EBITDA–$49.5 million year-on-year increase Trending: If there was a new fund backed by Jeff Bezos offering a ? The earnings release included a statement from CEO Eric Lefkofsky. "Our performance in 2024 reflects the strength of our core businesses, as Genomics continued to show strong volume growth, and our Data business delivered record results throughout the year," he said. Despite Lefkofsky's rosy outlook, Tempus AI shares fell sharply on cost concerns and are currently trading at $59.10. That's a precipitous fall from Tempus AI's 2025 high of $89.71, which it hit on Feb. 18. However, Tempus AI was trading in the $50 range right before news of Pelosi's options trades broke. Benzinga's survey of 11 analysts shows a consensus price target of $60.44 for Tempus AI, but the most recent targets from Needham, JPMorgan, and TD Cowan average $66.33, meaning there is still upside either case, Pelosi's reported strike price of $20 means she stands to make a solid profit on her investment. It's also worth noting that Guggenheim, JP Morgan, and Needham all assigned a "Buy Now" recommendation to Tempus on Feb. 25. They clearly share Pelosi's opinion that Tempus AI stock has strong upside potential. is another fan of Tempus AI. Benzinga reports that Wood's Ark Genomic Revolution ETF purchased 78,570 shares, while the Ark Innovation ETF recently purchased 367,388 Tempus shares in deals totaling just over $26 million. The short version of the story is that a lot of very astute investors are enamored with Tempus AI. If you're looking for an affordable AI stock with upside, Tempus AI might be worth considering. Wondering if your investments can get you to a $5,000,000 nest egg? Speak to a financial advisor today. to decide which one is right for you. Lower interest rates mean some investments won't yield what they did in months past, but you don't have to lose those gains. Certain private market real estate investments are giving retail investors the opportunity to capitalize on these high-yield opportunities. , which provides access to a pool of short-term loans backed by residential real estate. The best part? Unlike other private credit funds, Looking for fractional real estate investment opportunities? The features the latest offerings. This article Why Does Nancy Pelosi Like Tempus AI (TEM) Stock So Much? originally appeared on Sign in to access your portfolio
